Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Howland Capital Management LLC

Howland Capital Management LLC trimmed its holdings in Illumina, Inc. (NASDAQ:ILMN) by 3.6% during the fourth quarter, HoldingsChannel.com reports. The firm owned 20,287 shares of the life sciences company’s stock after selling 766 shares during the period. Howland Capital Management LLC’s holdings in Illumina were worth $2,711,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Cetera Investment Advisers raised its position in shares of Illumina by 25.8% during the 2nd quarter. Cetera Investment Advisers now owns 18,384 shares of the life sciences company’s stock valued at $1,919,000 after acquiring an additional 3,767 shares in the last quarter. Diversified Trust Co acquired a new stake in shares of Illumina during the 3rd quarter valued at approximately $243,000. CWM LLC raised its position in shares of Illumina by 179.8% during the 3rd quarter. CWM LLC now owns 16,207 shares of the life sciences company’s stock valued at $2,114,000 after acquiring an additional 10,414 shares in the last quarter. Perpetual Ltd acquired a new stake in shares of Illumina during the 3rd quarter valued at approximately $723,000. Finally, UMB Bank n.a. raised its position in shares of Illumina by 23.7% during the 3rd quarter. UMB Bank n.a. now owns 1,659 shares of the life sciences company’s stock valued at $216,000 after acquiring an additional 318 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on ILMN. Guggenheim dropped their price target on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday. Citigroup downgraded Illumina from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $190.00 to $165.00 in a research note on Wednesday, December 11th. Canaccord Genuity Group lowered their price objective on Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research note on Friday. UBS Group upped their price objective on Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Finally, Leerink Partners upped their price objective on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Nine equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Illumina has a consensus rating of “Moderate Buy” and a consensus target price of $161.40.

Illumina Stock Performance

Shares of ILMN stock opened at $111.06 on Friday. The stock has a 50-day simple moving average of $136.70 and a 200 day simple moving average of $135.29. Illumina, Inc. has a fifty-two week low of $100.08 and a fifty-two week high of $156.66. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. On average, equities analysts predict that Illumina, Inc. will post 4.42 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.